ConductScience.org, home

Paper · 40468448

References59

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129134745Mechanosignalling in tumour progression.J Cell Mol Med2018https://conductscience.org/library/papers/29134745PubMed
230279728Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.Theranostics2018https://conductscience.org/library/papers/30279728PubMed
328754442Mechanotransduction at the cell-matrix interface.Semin Cell Dev Biol2017https://conductscience.org/library/papers/28754442PubMed
433538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
517613324Demystifying the effects of a three-dimensional microenvironment in tissue morphogenesis.Methods Cell Biol2007https://conductscience.org/library/papers/17613324PubMed
629048430Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines.Cell Death Dis2017https://conductscience.org/library/papers/29048430PubMed
716169468Tensional homeostasis and the malignant phenotype.Cancer Cell2005https://conductscience.org/library/papers/16169468PubMed
832472133Dynamic extracellular matrix stiffening induces a phenotypic transformation and a migratory shift in epithelial cells.Integr Biol (Camb)2020https://conductscience.org/library/papers/32472133PubMed
929510460The extracellular matrix as a key regulator of intracellular signalling networks.Br J Pharmacol2019https://conductscience.org/library/papers/29510460PubMed
1019931152Matrix crosslinking forces tumor progression by enhancing integrin signaling.Cell2009https://conductscience.org/library/papers/19931152PubMed
1127396337Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer.Cell Rep2016https://conductscience.org/library/papers/27396337PubMed
1239744441TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling.Int J Biol Sci2025https://conductscience.org/library/papers/39744441PubMed
1319567681Kinome profiling in pediatric brain tumors as a new approach for target discovery.Cancer Res2009https://conductscience.org/library/papers/19567681PubMed
1425959051Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration.Integr Biol (Camb)2015https://conductscience.org/library/papers/25959051PubMed
1532832636Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.Sci Adv2020https://conductscience.org/library/papers/32832636PubMed
1634063627JNK in Tumor Microenvironment: Present Findings and Challenges in Clinical Translation.Cancers (Basel)2021https://conductscience.org/library/papers/34063627PubMed
1716632515Adjusting batch effects in microarray expression data using empirical Bayes methods.Biostatistics2007https://conductscience.org/library/papers/16632515PubMed
1821547576Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study.Cell Oncol (Dordr)2011https://conductscience.org/library/papers/21547576PubMed
1924978026Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.PLoS One2014https://conductscience.org/library/papers/24978026PubMed
2032147542Fibrosis and cancer: A strained relationship.Biochim Biophys Acta Rev Cancer2020https://conductscience.org/library/papers/32147542PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/40468448/references